Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption
Standardized CAR-T cells from healthy donors could eventually make this powerful cancer therapy available to far more patients worldwide if researchers solve durability and rejection challenges.
Allogeneic CAR-T cells derived from healthy donors and manufactured in standardized batches could make cellular immunotherapy globally scalable, overcoming the per-patient manufacturing constraints of autologous CAR-T. This comprehensive review synthesizes genome-editing strategies (TCR knockout, HLA modulation), clinical trial data, and translational barriers, identifying immune rejection and engraftment durability as the principal unresolved challenges.
What the study was
- Study design
- Narrative review
- Category
- T6: Novel therapeutics: immunotherapy, CAR-T, targeted therapy
- Maturity
- Exploratory
- Journal
- Med Rev (2021)
Why it surfaced
Directly addresses allogeneic/universal CAR-T—an explicit watchlist target—with synthesis of clinical trial evidence and engineering strategy mapping; transformative potential for hematologic malignancies and solid tumors at scale.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.